行业盛典 再启新程|第七届中国医药创新与投资大会初版日程发布

YANG Dajun

Chairman of PhIRDA Drug R&D Specialty Committee, Chairman of the Board & CEO of Ascentage Pharma

Dajun Yang, Ph.D.,is the Co-Founder, Chairman of the Board, and Chief Executive Officer of Ascentage Pharma. Dr. Yang has dedicated his career to the research on apoptosis and innovative drug R&D for nearly 30 years. In 2009, he co-founded Ascentage Pharma and made major breakthroughs in the research of development of precision drugs targeting apoptosis and autophagy dual-channel regulation. Ascentage Pharma is the only company in the world that researches and develops innovative drugs targeting all of these pathways. Ascentage Pharma currently has eight potential “First-inclass” or “Best-in-class” innovative drug candidates in Phase I/II clinical developments in China, the United States, Australia and Europe. Dr. Yang has undertaken nearly ten National Science and Technology Major Projects such as the National High-tech R&D Program (the “863 Program”) and the Major Innovative Drug Developments program. The team led by Dr. Yang has won multiple awards such as the Major Innovation Team of Suzhou and Jiangsu, the First Jiangsu Innovation Competition Team Award, and the R&D Achievement of the Year 2017 from the BayHelix Group. Dr. Yang is the recipient of the 2018 “Dushu Lake Prize” for the Most Influential Leader in Drug R&D, an award widely recognized in the field drug R&D.